Department of Pharmacy, Barnes Jewish Hospital, St Louis, Missouri, USA.
World Neurosurg. 2011 Feb;75(2):269-74. doi: 10.1016/j.wneu.2010.09.002.
The optimal regimen for seizure prophylaxis after subarachnoid hemorrhage (SAH) remains uncertain. Based on data suggesting that a short course may be adequate, coupled with an association between phenytoin exposure and poor cognitive outcome, our institution modified their seizure prophylaxis protocol for patients with SAH from an extended course of phenytoin to 3 days of levetiracetam. This study sought to compare the incidence of seizures before and after this change to evaluate whether a short course of levetiracetam would be as effective in preventing in-hospital seizures.
This study analyzed 442 consecutive patients admitted with SAH between January 2003 and January 2008, including 297 patients treated before the protocol change (PHT group) and 145 treated afterward (LEV group). Occurrence of all seizures was extracted from a prospectively collected intensive care unit database and further review of medical records. In-hospital seizures were divided into early (occurring on or before day 3, all patients on prophylaxis) and those occurring late (after day 3, LEV group off prophylaxis).
In-hospital seizures occurred in 3.4% of the PHT group and 8.3% of the LEV group (P = 0.03). Although the rate of early seizures was not different (1.4% PHT vs. 2.8% LEV, P = 0.45), there was a higher rate of late seizures (2% PHT vs. 5.5% LEV, P = 0.05).
The use of short-duration levetiracetam for seizure prophylaxis after SAH was associated with a higher rate of in-hospital seizures than an extended course of phenytoin, mainly related to an increase in late seizures, when the levetiracetam had been discontinued. This suggests that a longer duration of prophylaxis may be required to minimize seizures in patients with SAH, although confirmatory studies are required.
蛛网膜下腔出血(SAH)后预防癫痫发作的最佳方案仍不确定。基于数据表明短疗程可能足够,并且苯妥英暴露与认知结局不良之间存在关联,我们机构修改了他们对 SAH 患者的癫痫预防方案,将苯妥英的延长疗程改为左乙拉西坦 3 天。本研究旨在比较该改变前后癫痫发作的发生率,以评估短疗程左乙拉西坦是否同样有效地预防住院期间的癫痫发作。
本研究分析了 2003 年 1 月至 2008 年 1 月期间连续收治的 442 例 SAH 患者,包括 297 例在方案改变前(PHT 组)和 145 例改变后(LEV 组)治疗的患者。所有癫痫发作均从前瞻性收集的重症监护病房数据库中提取,并进一步查阅病历。将住院期间的癫痫发作分为早期(发生在或之前的第 3 天,所有预防用药的患者)和晚期(第 3 天之后,LEV 组停止预防用药)。
PHT 组和 LEV 组的住院期间癫痫发作发生率分别为 3.4%和 8.3%(P = 0.03)。虽然早期癫痫发作的发生率无差异(PHT 组 1.4%,LEV 组 2.8%,P = 0.45),但晚期癫痫发作的发生率较高(PHT 组 2%,LEV 组 5.5%,P = 0.05)。
与延长疗程的苯妥英相比,SAH 后使用短疗程左乙拉西坦进行癫痫预防与更高的住院期间癫痫发作率相关,主要与停药后晚期癫痫发作增加有关。这表明,为了最大限度地减少 SAH 患者的癫痫发作,可能需要更长的预防疗程,尽管需要进行确认性研究。